Clinical applications and challenges of CD40/CD40L signaling regulation in autoimmune diseases - Top-Institutions - MDSpire

Clinical applications and challenges of CD40/CD40L signaling regulation in autoimmune diseases

  • By

  • Yangyang Man

  • Xiaoni Chen

  • Yi Liu

  • Biao Zhang

  • Jiahua Hu

  • Xianliang Hou

  • May 18, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins Medicine
    Johns Hopkins Medicine

    Baltimore, Maryland

    Key Differentiators

    • Rheumatology
    • Immunology

  • #2

    Hospital for Special Surgery
    Hospital for Special Surgery

    New York, New York

    Key Differentiators

    • Rheumatology
    • Immunology

  • #3

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Immunology

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Rheumatology
    • Immunology

  • #5

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Immunology

Original Source(s)

Clinical applications and challenges of CD40/CD40L signaling regulation in autoimmune diseases

  • by Yangyang Man, Xiaoni Chen, Yi Liu, Biao Zhang, Jiahua Hu, Xianliang Hou

  • May 18, 2026

Related Content

Neoadjuvant Single-Cycle Pembrolizumab for Stage I to III dMMR Colon Cancer

In a Danish phase II trial (RESET-C) reported in the Journal of Clinical Oncology, Gögenur et al found that a single cycle of neoadjuvant pembrolizumab was associated with pathologic complete response...

Study Finds Prostate Cancer Overdiagnosis Rises ‘Substantially’ With Age

Investigators have found that overdiagnosis of prostate cancer through prostate-specific antigen screening is low in younger men—but rises sharply with age.

FDA Approves Fam-Trastuzumab Deruxtecan-nxki Indications in HER2-Positive Early Breast Cancer

On May 15, 2026, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu) for two separate indications for the treatment of adult patients with HER2-positive earl...